AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06455748
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone: dex C1: 20mg IV D1/8, 20mg PO D2/9 and 40mg PO C1D15 weekly up to C6, then 20mg IV monthly starting C7D1 and 20mg PO D8, 15, 22.
Trial: NCT05995704
Drug: Apraglutide
RxNorm normalized name: Apraglutide
DrugBank: Apraglutide (DB18084)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peptide analogue of GLP-2
Trial: NCT05590572
Drug: Sulfatinib
RxNorm normalized name: SULFATINIB
DrugBank: Surufatinib (DB15106)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (1) Sulfatinib: 300 mg, oral once a day (QD), 21 days as a cycle
Trial: NCT05590572
Drug: Etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: (1) Etoposide: 100 mg/m2/day (initial dose) will be administered on the first to third days of each 21 day cycle, a total of 5 cycles. The dose of etoposide can be reduced to 80 mg/m2/day and 60 mg/m2/day.;
Trial: NCT05590572
Drug: Isophosphamide
RxNorm normalized name: Isophosphamide
DrugBank: Ifosfamide (DB01181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: (1) Isophosphamide: 3000 mg/m2/day (initial dose) will be administered on the first to third days of each 21 day cycle for 5 cycles. The dose of ifosfamide can be reduced to 2400 mg/m2/day and 1800 mg/m2/day.
Trial: NCT05339334
Drug: PF-07321332/ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: PF-07321332/ritonavir will be given by mouth two times a day for 10 days
Trial: NCT05013437
Drug: Evomela
RxNorm normalized name: Evomela
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 16 mg/m\^2 Evomela administered one time via a central line
Trial: NCT05013437
Drug: Prochlorperazine
RxNorm normalized name: Prochlorperazine
DrugBank: Prochlorperazine (DB00433)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10mg once intravenous (IV) within 30 minutes before Evomela
Trial: NCT05013437
Drug: Diphenhydramine
RxNorm normalized name: Diphenhydramine
DrugBank: Diphenhydramine (DB01075)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50 mg once intravenously within 30 minutes before Evomela
Trial: NCT06548815
Drug: GZR4
RxNorm normalized name: Grazoprevir
DrugBank: Grazoprevir (DB11575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ascending single doses - 4 dose levels.
Trial: NCT06378827
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexmedetomidine solution will be prepared by diluting one ampoule of dexmedetomidine (200µg/2ml) with 48 ml of saline solution to obtain a dexmedetomidine solution of 4µg/ml. Patients from the experimental group will receive a continuous infusion of dexmedetomidine at a dose of 0.5 µg/kg/h, until the end of the operation.
Trial: NCT06634056
Drug: Pentoxifylline
RxNorm normalized name: Pentoxifylline
DrugBank: Pentoxifylline (DB00806)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pentoxifylline 400 mg orally three times a day and α-Tocopherol IU orally two times a day on day one of radiotherapy and continue treatment for 6 months.
Trial: NCT01858103
Drug: BMN 110
RxNorm normalized name: DNA (synthetic adeno-associated virus 5 vector BMN 270 human blood-coagulation factor VIII SQ variant-specifying)
DrugBank: Tipapkinogene sovacivec (DB06239)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05252598
Drug: Psilocybin
RxNorm normalized name: Psilocybin
DrugBank: Psilocybin (DB11664)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1mg encapsulated psilocybin
Trial: NCT05267626
Drug: AU-007
RxNorm normalized name: camphor 0.007 MG/MG
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Monoclonal Antibody Targeting IL-2
Trial: NCT05267626
Drug: Aldesleukin
RxNorm normalized name: Aldesleukin
DrugBank: Aldesleukin (DB00041)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IL-2
Trial: NCT05267626
Drug: Avelumab
RxNorm normalized name: Avelumab
DrugBank: Avelumab (DB11945)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Monoclonal Antibody Targeting PD-L1
Trial: NCT05011396
Drug: PH94B Nasal Spray
RxNorm normalized name: PH94B
DrugBank: PH94B (DB04968)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal spray delivered 20 minutes before the public speaking stressor
Trial: NCT05666089
Drug: N-acetyl cysteine
RxNorm normalized name: N-Acetyl Cysteine
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intracanal medication of NAC with concentration 1 gm/ml in the form of a paste
Trial: NCT05990803
Drug: BL-B01D1
RxNorm normalized name: BL-1020
DrugBank: BL-1020 (DB05687)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BL-B01D1 was administered by intravenous infusion on D1 and D8 in a 3-week cycle.
Trial: NCT05990803
Drug: SI-B003
RxNorm normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SI-B003 was administered by intravenous infusion every 3 weeks (Q3W).
Trial: NCT05731960
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 10 mg IV dexamethasone provided immediately after spinal anesthesia
Trial: NCT05731960
Drug: Metoclopramide
RxNorm normalized name: Metoclopramide
DrugBank: Metoclopramide (DB01233)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 mg IV metoclopramide provided immediately after spinal anesthesia
Trial: NCT00203684
Drug: Flunisolide-HFA
RxNorm normalized name: Flunisolide
DrugBank: Flunisolide (DB00180)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04738955
Drug: Micafungin Sodium
RxNorm normalized name: Micafungin Sodium
DrugBank: Micafungin (DB01141)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: micafungin sodium ≥ 100, \<200mg/time, once a day, intravenous drip. Low dose group
Trial: NCT05699655
Drug: Tislelizumab
RxNorm normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive Tislelizumab, 200mg, intravenously over 30 - 60 minutes, day 1 of every 3 weeks for 4 cycles. Discontinuation will be considered due to toxicity, withdrawal of consent, or end of study. Every 3-week treatment period was considered to be a cycle.
Trial: NCT05699655
Drug: apatinib
RxNorm normalized name: Apatinib
DrugBank: Rivoceranib (DB14765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive apatinib, 250mg, qd，every 3 weeks for 3 weeks
Trial: NCT05699655
Drug: oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants will receive oxaliplatin, 130mg/m2, day 1 of every 3 weeks for 4 weeks.
Trial: NCT05699655
Drug: S-1
RxNorm normalized name: LIS-1
DrugBank: Tegafur (DB09256)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Participants will receive S-1, day 1-14 of every 3 weeks for 4 weeks.
Trial: NCT05896007
Drug: Zanubrutinib
RxNorm normalized name: Zanubrutinib
DrugBank: Zanubrutinib (DB15035)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 160 mg bid po, until disease progression, intolerance of drug toxicity or death, otherwise maintaining during the 1st year in 2 years of follow-up
Trial: NCT05896007
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 375 mg/m\^2 ivgtt, D0 of each 28-day cycle
Trial: NCT05896007
Drug: Temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 150 mg/m\^2 ivgtt, D1-D5 of each 28-day cycle
Trial: NCT06033729
Drug: Midazolam injection
RxNorm normalized name: midazolam Injection
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Bolus administration of midazolam (1-2 mg)and/or until a Ramsey score 2-3 was reached
Trial: NCT06033729
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bolus adminitration of propofol until a Ramsey score 2-3 was reached
Trial: NCT04702737
Drug: Tarlatamab
RxNorm normalized name: Tarlatamab
DrugBank: Tarlatamab (DB17256)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tarlatamab will be administered as an intravenous (IV) infusion.
Trial: NCT06399783
Drug: Mometasone Furoate
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients will be treated by fractional CO2 laser for 6 sessions each will be followed immediately by topical application of Mometasone Furoate.
Trial: NCT04939857
Drug: Trimetazidine
RxNorm normalized name: trimetazidine
DrugBank: Trimetazidine (DB09069)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The experimental group will be treated with trimetazidine, and the control group will not be intervened
Trial: NCT00000312
Drug: M-CPP
RxNorm normalized name: M-CPP
DrugBank: m-Chlorophenylpiperazine (DB12110)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05707754
Drug: Bupivacaine
RxNorm normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topically applied to sphenopalatine ganglion
Trial: NCT04937023
Drug: Ursodeoxycholic acid gel
RxNorm normalized name: ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Following scaling and root planing in intrabony defects UDCA gel will be injected
Trial: NCT06166836
Drug: D1553
RxNorm normalized name: Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: D1553 orally taken，600mg twice a day
Trial: NCT06166836
Drug: IN10018（Ifebemtinib）
DrugBank: Ifebemtinib (DB17570)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IN10018 orally taken once daily at approximately the same time each day
Trial: NCT02759042
Drug: PRO 140
RxNorm normalized name: Climara Pro
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: PRO 140 is a humanized IgG4,κ monoclonal antibody (mAb) to the chemokine receptor CCR5.
Trial: NCT06364046
Drug: Serplulimab
RxNorm normalized name: Serplulimab
DrugBank: Serplulimab (DB17451)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Programmed cell death protein 1 inhibitor fixation was treated with serplulimab (Fuhong Hanlin Co., LTD.). It is administered by intravenous infusion, and the recommended dose is 200 mg, given once every 21 days. The medication will last for two years until disease progression or intolerable toxicity occurs. During immunotherapy, immunosuppressive agents will not be replaced and the dose will not be adjusted.
Trial: NCT05265650
Drug: BO-112 in combination with ablative radiotherapy (SABR) and nivolumab
RxNorm normalized name: nivolumab and relatlimab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Study treatment will consist of BO-112 IT injections in combination with IV nivolumab infusions and SABR to accessible metastases.
Trial: NCT06326944
Drug: Pethidine
RxNorm normalized name: Pethidine
DrugBank: Meperidine (DB00454)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pethidine IV will be given as rescue analgesia (0.5 mg/kg) if the FLACC pain score was more than 4 , the maximum allowed dose is 1mg/kg every 4 hours.
Trial: NCT06294600
Drug: Tablets
RxNorm normalized name: Mesna Tablets
DrugBank: Coenzyme M (DB09110)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablets of similar appearance to active study drug
Trial: NCT04378426
Drug: Nitrous Oxide
RxNorm normalized name: Nitrous Oxide
DrugBank: Nitrous oxide (DB06690)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PTSD participants in this arm will receive and admixture of up to 50% nitrous oxide and 50% oxygen plus intravenous saline
Trial: NCT04378426
Drug: Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: PTSD participants in this arm will receive and admixture of up to 50%nitrogen and 50% oxygen plus intravenous 0.045mg/kg midazolam
Trial: NCT04378426
Drug: Nitrogen
RxNorm normalized name: Nitrogen
DrugBank: Nitrogen (DB09152)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PTSD participants in this arm will receive and admixture of up to 50%nitrogen and 50% oxygen plus intravenous 0.045mg/kg midazolam
Trial: NCT04378426
Drug: Oxygen
RxNorm normalized name: Oxygen
DrugBank: Oxygen (DB09140)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: inhaled gas
Trial: NCT04378426
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Placebo infusion
Trial: NCT05485207
Drug: Transvaginal botulinum toxin A (BTA) injection
RxNorm normalized name: Botulinum toxin type A
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Botulinum toxin A (Botox® 100 units) will be injected into the detrusor muscle of the bladder by inserting a needle through the anterior vaginal wall.
Trial: NCT05422092
Drug: Canagliflozin
RxNorm normalized name: Canagliflozin
DrugBank: Canagliflozin (DB08907)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 40 patients with T2DM combined with NAFLD, who have poor glycemic control response to metformin monotherapy, will be randomly assigned to receive canagliflozin on top of metformin as experimental group.
Trial: NCT05422092
Drug: Pioglitazone
RxNorm normalized name: Pioglitazone
DrugBank: Pioglitazone (DB01132)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 40 patients with T2DM combined with NAFLD, who have poor glycemic control response to metformin monotherapy, will be randomly assigned to receive pioglitazone 45mg on top of metformin as placebo comparator group.
Trial: NCT04954365
Drug: Amisulpride
RxNorm normalized name: Amisulpride
DrugBank: Amisulpride (DB06288)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rescue Post-Operative Nausea and Vomiting (PONV) treatment with Amisulpride
Trial: NCT04987281
Drug: Indocyanine Green Solution
RxNorm normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given via injection
Trial: NCT05634577
Drug: Mitotane
RxNorm normalized name: Mitotane
DrugBank: Mitotane (DB00648)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given by PO
Trial: NCT05634577
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given by vein (IV)
Trial: NCT05277974
Drug: inj bupivicain
RxNorm normalized name: bupivacaine Injection
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In goup B 30ml of inj. bupivicaine only will be given in Erector Spinae Plane Block and In Group D inj Bupivicain plus inj dexamethasone will be given
Trial: NCT04774250
Drug: Zonisamide 100Mg Cap
RxNorm normalized name: ZONISAMIDE 100MG CAP
DrugBank: Zonisamide (DB00909)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: ZONEGRAN® is commercially available for oral administration as capsules containing 100 mg of Zonisamide.
Trial: NCT05529004
Drug: Oral Capsule pregapalin
RxNorm normalized name: pregabalin Oral Capsule
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: oral cap of pregapalin has been administration to patient before surgery to prvent PONV
Trial: NCT05117177
Drug: Inupadenant
RxNorm normalized name: Inupadenant
DrugBank: Inupadenant (DB19129)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration
Trial: NCT05498116
Drug: Montelukast
RxNorm normalized name: Montelukast
DrugBank: Montelukast (DB00471)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10mg daily
Trial: NCT05168930
Drug: Venetoclax
RxNorm normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: C4-15
Trial: NCT05168930
Drug: Zanubrutinib
RxNorm normalized name: Zanubrutinib
DrugBank: Zanubrutinib (DB15035)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: C1-15
Trial: NCT00000790
Drug: Thalidomide
RxNorm normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT05704114
Drug: Tazarotene 0.045% Lotion
RxNorm normalized name: TAZAROTENE 0.045% LOTION
DrugBank: Tazarotene (DB00799)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daily topical use of tazarotene for 16 weeks.
Trial: NCT04802837
Drug: Ridinilazole
RxNorm normalized name: Ridinilazole
DrugBank: Ridinilazole (DB15308)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ridinilazole 200mg dosed BID for 10 days.
Trial: NCT04802837
Drug: Vancomycin
RxNorm normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vancomycin 125mg dosed QID for 10 days.
Trial: NCT06334367
Drug: CD25 treatment
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CD25 prophylaxis
Trial: NCT06334367
Drug: low-dose ATG
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: HSCT pre-treatment with 7.5mg/Kg ATG(2.5mg/Kg/d) at day -4, -3 and -2.
Trial: NCT05532397
Drug: QPOP category 1
RxNorm normalized name: lipase
DrugBank: Pancrelipase (DB00085)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: combination regimens with published data in the setting of gliomas
Trial: NCT05532397
Drug: QPOP category 2
RxNorm normalized name: lipase
DrugBank: Pancrelipase (DB00085)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: combination regimens where there is published data on intracranial activity and anti-glioma effect of the individual agents either as monotherapy or in combination with other agents, and where there is published safety data on the combination
Trial: NCT05841472
Drug: Camrelizumab (SHR-1210), Pemetrexed, and Carboplatin
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: * 200 mg of Camrelizumab (SHR-1210) is administered intravenously over a period of around 20-60 min on Day 1 of each 3-week cycle.~* Pemetrexed 500 mg/m2 is administered intravenously on Day 1 of each 3-week cycle, over a period of more than 10 minutes~* Carboplatin of AUC 5 is administered intravenously on Day 1 of each 3-week cycle (hydrated as appropriate), over a period of more than 30 minutes by 4-6 cycles.
Trial: NCT05212025
Drug: Adavosertib
RxNorm normalized name: Adavosertib
DrugBank: Adavosertib (DB11740)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taken Orally
Trial: NCT05212025
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous Infusion
Trial: NCT05533801
Drug: Lecanemab
RxNorm normalized name: Lecanemab
DrugBank: Lecanemab (DB14580)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lecanemab will be administered subcutaneously using a vial and syringe.
Trial: NCT05533801
Drug: Lecanemab
RxNorm normalized name: Lecanemab
DrugBank: Lecanemab (DB14580)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lecanemab will be administered subcutaneously using AI.
Trial: NCT05431244
Drug: Antiviral treatment in combination with low-dose gemcitabine
RxNorm normalized name: ethinyl estradiol
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: -maximun 6 cycles Gemcitabine; 30mg/m2 or 100mg/m2 or 300mg/m2 D1,D8, D15 (Q 1 week,3 times, rest for 1 week, every 4 weeks ) 1,2 cycle Valganciclovir; 900mg D8\~D28 (from 1 week after Gemcitabine iv started, qd, PO, 21days) 3\~6cycle Valganciclovir; 900mg D1\~D28 (from Gemcitabine start date, PO, 28days)
Trial: NCT00002283
Drug: Trimethoprim
RxNorm normalized name: Trimethoprim
DrugBank: Trimethoprim (DB00440)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002283
Drug: Sulfamethoxazole
RxNorm normalized name: Sulfamethoxazole
DrugBank: Sulfamethoxazole (DB01015)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002283
Drug: Dapsone
RxNorm normalized name: Dapsone
DrugBank: Dapsone (DB00250)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04727541
Drug: Bintrafusp alfa
RxNorm normalized name: Bintrafusp alfa
DrugBank: Bintrafusp alfa (DB15387)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant therapy with bintrafusp alfa
Trial: NCT06266221
Drug: Prednisone 20 Mg
RxNorm normalized name: prednisone 20 MG
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral corticosteriods
Trial: NCT06266221
Drug: Methylprednisolone 120 Mg
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV corticosteriods
Trial: NCT04708834
Drug: Troriluzole (BHV-4157)
RxNorm normalized name: Troriluzole
DrugBank: Troriluzole (DB15079)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg daily first 2 weeks, 280 daily following first 2 weeks
Trial: NCT05534646
Drug: Apalutamide
RxNorm normalized name: Apalutamide
DrugBank: Apalutamide (DB11901)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Standard of care Apalutamide 240 mg administered orally and daily on Days 1-28 of every 28 day cycle
Trial: NCT05534646
Drug: Carotuximab
RxNorm normalized name: Carotuximab
DrugBank: Carotuximab (DB06322)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carotuximab administered intravenously at the following doses:~Cycle 1 Day 1: 3 mg/kg Cycle 1 Day 4: 7 mg/kg Cycle 1 Day 8: 10 mg/kg Cycle 1 Day 15: 10 mg/kg Cycle 1 Day 22: 10 mg/kg Cycle 2 Day 1: 15 mg/kg Cycle 2 Day 15: 15 mg/kg Cycle 3+ Day 1: 15 mg/kg After completion of cycle 2, dosing of carotuximab will continue at a q4 week schedule using the 15 mg/kg dose.
Trial: NCT06437223
Drug: Tonabersat
RxNorm normalized name: Tonabersat
DrugBank: Tonabersat (DB06578)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tonabersat 40mg. Two tablets per day
Trial: NCT04791579
Drug: Ciprofloxacin
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluoroquinolone antibiotic
Trial: NCT05112939
Drug: CAB LA
RxNorm normalized name: K-CAB
DrugBank: Tegoprazan (DB16690)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CAB LA will be administered at formulation 3.
Trial: NCT04782622
Drug: Apatinib+Camrelizumab
RxNorm normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apatinib 250mg po qd+Camrelizumab 200mg ivdrip q14d